NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells

Autor: Cristina Ruiz-Herguido, M. Carmen Lafita-Navarro, Rocío Aguado, Lucía García-Gutiérrez, Matilde Cañelles, Francisco Martin, Javier León, Eva Garcia-Alegria, Anna Bigas, Kyle Sarnataro

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname
Cancer Lett. 2016 May 28;375(1):92-9
UCrea Repositorio Abierto de la Universidad de Cantabria

Chronic myeloid leukemia (CML) progresses from a chronic to a blastic phase, where the leukemic cells are proliferative and undifferentiated. The CML is nowadays successfully treated with BCR-ABL kinase inhibitors as imatinib and its derivatives. NUM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99aafa4733e68b1982edcf56dc7d003e
https://pubmed.ncbi.nlm.nih.gov/26944313